CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells

CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells

Source: 
Fierce Biotech
snippet: 

Personalized cell therapy CAR-T has made significant inroads in treating some forms of leukemia and lymphoma, but scientists hoping to translate the new technology to the second most common blood cancer—multiple myeloma—have faced some hurdles. A team at the University of Utah’s Huntsman Cancer Institute (HCI) has early evidence that a new target called CD229 may help overcome those challenges.